With annual revenues of greater than $250 million, Paratek is one of the largest independent antibiotics companies in the world. Its lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA is the first-choice antibiotic for patients with comorbidities or suspected resistant pathogens. Paratek’s specialty pharmaceutical platform enables both the development and commercialisation of new drugs to bring new innovative therapies to patients.
Contact Person
Aleks Engel
Go to Profile